Drug Trial Radar · NCT06004245
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
280
Planned (sponsor's estimate)
Start
Jan 25, 2024
Primary completion
May 31, 2027
Study completion May 31, 2027
Sponsor
- Lead sponsor
- Vividion Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 22, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first-in-human, Phase I, open-label, multicenter, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of VVD-133214 monotherapy, and in combination with bevacizumab or pembrolizumab, in participants with microsatellite instability (MSI) and/or deficient mismatch repair (dMMR) advanced solid tumors. VVD-133214 is an oral drug that acts on a protein called Werner (WRN), which may promote the growth of cancers that are MSI and/or dMMR. By acting on WRN, VVD-133214 may be able to block the growth of these types of cancer.
Conditions
- Advanced Solid Tumors
- Colorectal Cancer
Interventions
VVD-133214Drug
VVD-133214 will be administered orally and once daily (QD) in 3-week cycles.
PembrolizumabDrug
Pembrolizumab will be administered by intravenous (IV) infusion at a fixed dose of 200 mg on Day 1 of each 21-day cycle.
BevacizumabDrug
Bevacizumab will be administered by intravenous (IV) infusion at a fixed dose of 7.5 mg/kg on Day 1 of each 21-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events, with Severity Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI CTCAE v5.0)Time frame: From first dose of study drug(s) until 30 days after the final dose of VVD-133214 or 90 days after last dose of bevacizumab or pembrolizumab
- Incidence of Dose-Limiting ToxicitiesTime frame: Cycle 1 (1 cycle is 3 weeks)
Locations
57 sites in 11 countries. Site status is shown where the registry gives one.
University of Arizona Cancer Center
Tucson, Arizona · Not yet recruiting
City of Hope Cancer Center
Duarte, California · Recruiting
City of Hope at Irvine Lennar
Irvine, California · Recruiting
START Los Angeles
Los Angeles, California · Recruiting
The Angeles Clinic and Research Institute
Los Angeles, California · Not yet recruiting
Emory University School of Medicine
Atlanta, Georgia · Recruiting
University of Chicago
Chicago, Illinois · Not yet recruiting
Norton Cancer Institute - MDC
Louisville, Kentucky · Recruiting
University of Michigan
Ann Arbor, Michigan · Recruiting
START Midwest
Grand Rapids, Michigan · Recruiting
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey · Recruiting
Duke University
Durham, North Carolina · Completed
Oklahoma University Health Sciences Center
Oklahoma City, Oklahoma · Completed
SCRI Oncology Partners
Nashville, Tennessee · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
START San Antonio
San Antonio, Texas · Recruiting
START Mountain Region
West Valley City, Utah · Recruiting
West Virginia University Cancer Institute
Morgantown, West Virginia · Not yet recruiting
St Vincents Sydney
Darlinghurst, New South Wales, Australia · Recruiting
Alfred Hospital
Melbourne, Victoria, Australia · Recruiting
Cliniques universitaires de Saint Luc
Brussels, Belgium · Not yet recruiting
UZ Leuven Gasthuisberg
Ghent, Belgium · Recruiting
UZ Gent
Ghent, Belgium · Not yet recruiting
BCCA-Vancouver Cancer Centre
Vancouver, British Columbia, Canada · Completed
Princess Margaret Cancer Center
Toronto, Ontario, Canada · Recruiting
Beijing Cancer Hospital
Beijing, China · Recruiting
The Sixth Hospital, affiliated with Sun Yat-sen University
Guangzhou, China · Recruiting
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China · Recruiting
Rigshospitalet
København Ø, Denmark · Recruiting
CLCC Leon Berard Lyon
Lyon, France · Completed
Institut regional du Cancer de Montpellier
Montpellier, France · Not yet recruiting
Hôpital saint Antoine
Paris, France · Not yet recruiting
Hopital europeen Georges Pompidou
Paris, France · Not yet recruiting
Oncopole Claudius Regaud
Toulouse, France · Not yet recruiting
Gustave Roussy
Villejuif, France · Recruiting
Sarawak Public Hospital
Kuching, Sarawak, Malaysia · Recruiting
Kyungpook National University Chilgok Hospital
Daegu, South Korea · Recruiting
National Cancer Center
Gyeonggi-do, South Korea · Recruiting
Seoul National University Bundang Hospital
Seongnam-si, South Korea · Recruiting
Seoul National University Hospital
Seoul, South Korea · Recruiting
Showing 40 of 57 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.